Entities / Company
Sangamo Therapeutics.
American biotechnology company
- Reports this week
- 0
- Active events
- 0
- Connections
- 40
What's happening
Gone quiet
No new reports in 90+ days-
Sangamo Therapeutics and Coeptis Therapeutics Holdings, Inc. are both small-cap medical companies.Some support1 report
-
Sangamo Therapeutics develops gene therapy for Fabry disease, showing promise in improving quality of life, while market trends benefit AI stocks.Speculative1 report
-
A study evaluated gene therapy for Fabry disease patients involving ERT and Sangamo Therapeutics.Some support1 report
-
Sangamo Therapeutics experienced a rating change following an upward trend in its earnings estimates, which institutional investors use for valuation.Some support1 report
-
The FDA lifted a clinical trial hold on August 20, 2025, allowing trials to resume for companies including Sangamo Therapeutics and Bluebird.Some support1 report
-
FDA agreed to use eGFR slope for Sangamo Therapeutics' approval after data was presented at a congress in Kyoto on September 4, 2025.Some support2 reports
No events began in the chosen period. Widen it, or reset.
Around Sangamo Therapeutics this week
News at the entities that move Sangamo Therapeutics most-
FDA StructuralNRx Pharmaceuticals is undergoing a first-cycle review of an ANDA for ketamine, noting its strategic importance for the U.S. military and VA.Moves Sangamo Therapeutics
-
Eli Lilly and Company TransactionalEli Lilly CEO David A. Ricks issued a company statement, coinciding with shares jumping in New York premarket trading.Moves Sangamo Therapeutics
Connections
The 2 strongest of 40, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
The FDA provides regulatory clearance and approval pathways necessary for Sangamo Therapeutics' drug treatments.
-
Eli Lilly and Company Transactional
Sangamo granted Eli Lilly rights to use its proprietary capsid for research and clinical development.
History
Events by the month they beganJuly 2026
1 eventJune 2026
5 events- Sangamo Therapeutics develops gene therapy for Fabry disease, showing promise in improving quality of life, while market trends benefit AI stocks.
- A study evaluated gene therapy for Fabry disease patients involving ERT and Sangamo Therapeutics.
- Sangamo Therapeutics experienced a rating change following an upward trend in its earnings estimates, which institutional investors use for valuation.
- The FDA lifted a clinical trial hold on August 20, 2025, allowing trials to resume for companies including Sangamo Therapeutics and Bluebird.
- FDA agreed to use eGFR slope for Sangamo Therapeutics' approval after data was presented at a congress in Kyoto on September 4, 2025.